Why Cancer Screening Guidelines Change Over Time

This page is for anyone confused by changing cancer screening advice. It explains why guidelines change and how to read a new one.

A screening guideline is a judgment about a moving body of evidence, made by a panel, at a particular time. It is a conclusion of the form: for people like you, at this age, this test appears to do more good than harm, by roughly this much. Every part of that sentence can shift.

That is why guidelines change. It is not because the previous panel was careless or the science was wrong. It is because the evidence was updated, or a different panel weighed the same evidence differently.

Screening trials take decades. A trial that randomizes people in their forties has to follow them into their sixties before it can say much about deaths. Meanwhile the population, the technology, and treatment all change. That alters what early detection is worth.

Two recent examples show this clearly.

Breast cancer. In 2016 the USPSTF recommended screening every other year from 50 to 74, with the decision for women in their forties treated as an individual one. In 2024 it recommended screening every other year from 40 to 74 and gave it a Grade B. Two things drove that. Breast cancer incidence in younger women had been climbing about 2.0 percent per year between 2015 and 2019. And updated modeling estimated roughly 1.3 additional breast cancer deaths averted per 1,000 women when screening starts at 40 rather than 50. The benefit was larger among Black women, who face higher rates of the disease and of death at younger ages.

Colorectal cancer. In 2021 the USPSTF lowered the starting age from 50 to 45, giving ages 45 to 49 a Grade B while ages 50 to 75 kept a Grade A. The trigger was the same shape: rising incidence in younger adults.

Both changes were expansions, and both followed observed shifts in who is getting cancer.

This is the part that reads as disagreement and is not.

The American Cancer Society recommends women have the option of annual mammography from 40, should have it annually from 45 to 54, and may move to every other year at 55. The USPSTF recommends every other year from 40 to 74. Same disease, largely the same trials, different schedules.

The divergence comes from how each group values what screening costs. More frequent screening finds more cancers earlier. It also produces more false positives, more biopsies, and more overdiagnosis (finding cancers that would never have caused harm). USPSTF modeling estimates about 1,376 false positives and about 14 overdiagnosed cases per 1,000 women across a lifetime of biennial (every other year) screening from 40 to 74. Weighting those harms more heavily produces longer intervals. Weighting deaths averted more heavily produces shorter ones.

Neither weighting is objectively correct, because it is a value judgment, not a question of fact. That is why guidance in this area increasingly says the decision is yours to make with your clinician.

The letters are not a ranking of importance. They encode how confident the panel is and how large the net benefit is.

• A means high certainty of substantial net benefit. Offer it.
• B means high certainty of moderate benefit, or moderate certainty of moderate-to-substantial benefit. Offer it.
• C means the net benefit is small. Offer selectively, based on individual circumstances and preferences.
• D means moderate or high certainty of no net benefit, or that harms outweigh benefits. Discourage it.
• I means the evidence is insufficient to weigh benefits against harms at all.

A C is where shared decision-making genuinely lives. An I statement, such as the one on supplemental imaging for dense breasts, means unknown, not useless. The two are often confused.

In 2012 the USPSTF gave PSA screening a D for all men, having concluded the harms outweighed the benefits. In 2018 it revised that to a C for men aged 55 to 69, recommending an individual decision after discussing benefits and harms. It kept the D for men 70 and older.

The Task Force said the change rested in part on added evidence that raised its certainty about reduced deaths from prostate cancer, including longer follow-up of the European ERSPC trial. It also reflected new evidence about, and increased use of, active surveillance (close monitoring) of low-risk prostate cancer, which may reduce the harms that follow screening.

When a guideline changes, three questions usually settle whether it applies to you:

• Which organization issued it? ACS and USPSTF often differ.
• What grade does it carry? A C is an invitation to decide, not an instruction.
• Do your age, sex, and risk factors put you inside the group it addresses?

The change itself is not a warning sign. A guideline that had never moved in thirty years would be.

• USPSTF: Methods and processes
• USPSTF: Breast cancer screening recommendation (2024)
• USPSTF: Prostate cancer screening recommendation (2018)
• NCI: Cancer screening guidelines lack information on harms